Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

It’s Hard to Believe Pinterest Has Become a Contrarian Buy

The Pinterest honeymoon has come to an end. That doesn’t mean you shouldn’t consider picking up a few shares of PINS stock at current prices. 

Hiring Rick Dauch Was a Hail Mary by Workhorse

Can Rick Dauch turn Workhorse around after the lousy year they've had? It's hard to say, but WKHS stock is a bet on his leadership.

ContextLogic Isn’t Worth More Than a Couple of Bucks

ContextLogic is falling back to earth this summer. Trading as high as $30 in February, WISH stock is just over $7. Time to buy? 

The Chinese Government’s Grip on Alibaba Is Tightening

Alibaba trades at a low point in past 24 months. BABA stock is stuck in downtrend until the Chinese government relents. That’s unlikely.  

Robinhood Stock Relies Too Heavily on Crypto and Options to Be a Good Buy

Robinhood bucks IPO trend by starting poorly and taking off after its first day of trading. Can HOOD stock maintain its post-IPO momentum? 

10 Stocks to Buy Owned by the Top Female Portfolio Managers in America

A recent article highlighted the top 20 female portfolio managers in the U.S. Here are 10 stocks to buy from some of the funds they manage.

Should You Follow Jim Simons’ Lead and Jump on AMC Stock?

Hedge fund billionaire Jim Simons owns more than 1.8 million shares of AMC stock. That’s attracting attention. Should you follow his lead? 

AT&T Stock Doesn’t Have What It Takes To Get Back Above $30

AT&T announced a spinoff and merger of WarnerMedia with Discovery Communications in mid-May. T stock has lost 13% since then. Time to buy?  

Ocugen’s Facing a Major Uphill Climb Without FDA Approval

The quick FDA approval of Ocugen’s Covid-19 vaccine is fading with every passing day. As a result, OCGN stock is down 17% in the past week. 

ChargePoint Continues to Plot a Course to EV Charging Dominance

ChargePoint made two strategic acquisitions to strengthen its grip on EV charging infrastructure. Eventually, CHPT stock will benefit.